Search

Your search keyword '"Hyeon Seok An"' showing total 3,305 results
Start Over Author "Hyeon Seok An"
3,305 results on '"Hyeon Seok An"'

55. Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study

Author

Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee, Adult Acute Lymphoblastic Leukemia Working Party, and the Korean Society of Hematology

Subjects
survival, leukemia, acute lymphoblastic, rituximab, Medicine
Abstract

Background/Aims We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bone marrow expressed CD20 ≥ 20% at the time of diagnosis. Patients received multiagent chemotherapy with rituximab. After achieving complete remission (CR), patients received five cycles of consolidation with concomitant rituximab. Rituximab was administered monthly from day 90 of transplantation for patients who received allogeneic hematopoietic cell transplantation. Results In patients with Philadelphia (Ph)-negative ALL, 39 of 41 achieved CR (95.1%), the 2- and 4-year relapse-free survival (RFS) rates were 50.4% and 35.7%, and the 2- and 4-year overall survival (OS) rates were 51.5% and 43.2%, respectively. In the group with Ph-positive ALL, all 32 patients achieved CR, the 2- and 4-year RFS rates were 60.7% and 52.1%, and the 2- and 4-year OS rates were 73.3% and 52.3%, respectively. In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity. Patients who received ≥ 2 cycles of rituximab after transplantation had significantly improved RFS (hazard ratio [HR], 0.31; p = 0.049) and OS (HR, 0.29; p = 0.021) compared with those who received < 2 cycles. Conclusions The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials.gov NCT01429610).

Published
2023
Full Text
View/download PDF

57. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation

Author

Baek, Dong Won, Moon, Joon Ho, Lee, Jae Hoon, Kang, Ka-Won, Lee, Ho Sup, Eom, Hyeon-Seok, Lee, Enuyoung, Lee, Ji Hyun, Lee, Jeong-Ok, Park, Seong Kyu, Kim, Seok Jin, Yoo, Keon Hee, Yoon, Sung-Soo, Koh, Youngil, Kang, Hyoung Jin, Won, Jong-Ho, Lyu, Chuhl Joo, Hahn, Seung Min, Lee, Jung-Hee, Park, Joon Seong, Jo, Jae-Cheol, Mun, Yeung-Chul, Yang, Deok-Hwan, Song, Ga-Young, Lim, Sung-Nam, and Sohn, Sang Kyun

Published
2023
Full Text
View/download PDF

79. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Author

Song, Yuqin, Tilly, Hervé, Rai, Shinya, Zhang, Huilai, Jin, Jie, Goto, Hideki, Terui, Yasuhito, Shin, Ho-Jin, Kim, Won Seog, Cao, Junning, Feng, Jifeng, Eom, Hyeon Seok, Kim, Tae Min, Tsai, Xavier Cheng-Hong, Gau, Jyh-Pyng, Koh, Hideo, Zhang, Liling, Song, Yongping, Yang, Yu, Li, Wei, Huang, He, Ando, Kiyoshi, Sharman, Jeff P., Sehn, Laurie H., Bu, Lilian, Wang, Xin, Jiang, Yanwen, Hirata, Jamie, Lee, Calvin, Zhu, Jun, and Izutsu, Koji

Published
2023
Full Text
View/download PDF

81. Genome-informed investigation of the molecular evolution and genetic reassortment of severe fever with thrombocytopenia syndrome virus.

Author

Kyuyoung Lee, Jong Hyeon Seok, Hyunbeen Kim, Sejik Park, Sohyun Lee, Joon-Yong Bae, Kyeongseok Jeon, Jun-Gu Kang, Jeong Rae Yoo, Sang Taek Heo, Nam-Hyuk Cho, Keun Hwa Lee, Kisoon Kim, Man-Seong Park, and Jin Il Kim

Subjects
Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270
Abstract

BackgroundSevere fever with thrombocytopenia syndrome virus (SFTSV) is a viral pathogen causing significant clinical signs from mild fever with thrombocytopenia to severe hemorrhages. World Health Organization has paid special attention to the dramatic increase in human SFTS cases in China, Japan, and South Korea since the 2010s. The present study investigated the molecular evolution and genetic reassortment of SFTSVs using complete genomic sequences.Methods/principal findingWe collected the complete genome sequences of SFTSVs globally isolated until 2019 (L segment, n = 307; M segment, n = 326; and S segment, n = 564) and evaluated the evolutionary profiles of SFTSVs based on phylogenetic and molecular selection pressure analyses. By employing a time-scaled Bayesian inference method, we found the geographical heterogeneity of dominant SFTSV genotypes in China, Japan, and South Korea around several centuries before and locally spread by tick-born spillover with infrequent long-distance transmission. Purifying selection predominated the molecular evolution of SFTSVs with limited gene reassortment and fixed substitution, but almost all three gene segments appeared to harbor at least one amino acid residue under positive selection. Specifically, the nonstructural protein and glycoprotein (Gn/Gc) genes were preferential selective targets, and the Gn region retained the highest number of positively selected residues.Conclusion/significanceHere, the large-scale genomic analyses of SFTSVs improved prior knowledge of how this virus emerged and evolved in China, Japan, and South Korea. Our results highlight the importance of SFTSV surveillance in both human and non-human reservoirs at the molecular level to fight against fatal human infection with the virus.

Published
2023
Full Text
View/download PDF

91. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation

Author

Seok Jin Kim, Jae-Cheol Jo, Dok Hyun Yoon, Deok-Hwan Yang, Sang Eun Yoon, Gyeong-Won Lee, Jee Hyun Kong, Yong Park, Ka-Won Kang, Ho-Sup Lee, Sung Yong Oh, Ho-Jin Shin, Won Sik Lee, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Sung-Nam Lim, Ho-Young Yhim, Young Rok Do, Hwan Jung Yun, Hyeon-Seok Eom, Mark Hong Lee, Cheolwon Suh, and Won Seog Kim

Subjects
T-cell, lymphoma, chemotherapy, autologous stem cell transplantation, progression-free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionUpfront autologous stem cell transplantation (ASCT) has been recommended for patients who are newly diagnosed with peripheral T-cell lymphoma (PTCL), and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anthracycline-based chemotherapy has been the frontline chemotherapy for PTCL. However, it is not clear whether anthracycline-based chemotherapies such as CHOP could be standard induction therapy for PTCL.MethodsWe conducted a randomized phase II study to compare CHOP with fractionated ifosfamide, carboplatin, etoposide, and dexamethasone (ICED) for patients eligible for ASCT. The primary endpoint was progression-free survival (PFS) and secondary endpoints included objective response rate, overall survival (OS), and safety profiles.ResultsPatients were randomized into either CHOP (n = 69) or ICED (n = 66), and the characteristics of both arms were not different. PTCL-not otherwise specified (NOS, n = 60) and angioimmunoblastic T-cell lymphoma (AITL, n = 53) were dominant. The objective response rate was not different between CHOP (59.4%) and ICED (56.1%), and the 3-year PFS was not different between CHOP (36.7%) and ICED (33.1%). In AITL patients, CHOP was favored over ICED whereas ICED was associated with more cytopenia and reduced dose intensity. Patients who received upfront ASCT after achieving complete response to CHOP or ICED showed 80% of 3-year OS.DiscussionIn summary, our study showed no therapeutic difference between CHOP and ICED in terms of response and PFS. Thus, CHOP might remain the reference regimen especially for AITL based on its better outcome in AITL, and upfront ASCT could be recommended as a consolidation of complete response in patients with PTCL.

Published
2023
Full Text
View/download PDF

92. Corrigendum: Development and validation of urinary exosomal microRNA biomarkers for the diagnosis of acute rejection in kidney transplant recipients

Author

Jung-Woo Seo, Yu Ho Lee, Dong Hyun Tae, Yang Gyun Kim, Ju-Young Moon, Su Woong Jung, Jin Sug Kim, Hyeon Seok Hwang, Kyung-Hwan Jeong, Hye Yun Jeong, So-Young Lee, Byung Ha Chung, Chan-Duck Kim, Jae Berm Park, Junhee Seok, Yeong Hoon Kim, and Sang-Ho Lee

Subjects
kidney transplantation, acute rejection, urine, exosome, microRNA, Immunologic diseases. Allergy, RC581-607
Published
2023
Full Text
View/download PDF

99. Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants

Author

Yura Shin, Jeonghun Kim, Jong Hyeon Seok, Heedo Park, Hye-Ran Cha, Si Hwan Ko, Jae Myun Lee, Man-Seong Park, and Jung-Hwan Park

Subjects
Medicine, Science
Abstract

Abstract Due to the continuously mutating nature of the H3N2 virus, two aspects were considered when preparing the H3N2 microneedle vaccines: (1) rapid preparation and (2) cross-protection against multiple antigenic variants. Previous methods of measuring hemagglutinin (HA) content required the standard antibody, thus rapid preparation of H3N2 microneedle vaccines targeting the mutant H3N2 was delayed as a result of lacking a standard antibody. In this study, H3N2 microneedle vaccines were prepared by high performance liquid chromatography (HPLC) without the use of an antibody, and the cross-protection of the vaccines against several antigenic variants was observed. The HA content measured by HPLC was compared with that measured by ELISA to observe the accuracy of the HPLC analysis of HA content. The cross-protection afforded by the H3N2 microneedle vaccines was evaluated against several antigenic variants in mice. Microneedle vaccines for the 2019–20 seasonal H3N2 influenza virus (19–20 A/KS/17) were prepared using a dip-coating process. The cross-protection of 19–20 A/KS/17 H3N2 microneedle vaccines against the 2015–16 seasonal H3N2 influenza virus in mice was investigated by monitoring body weight changes and survival rate. The neutralizing antibody against several H3N2 antigenic variants was evaluated using the plaque reduction neutralization test (PRNT). HA content in the solid microneedle vaccine formulation with trehalose post-exposure at 40℃ for 24 h was 48% and 43% from the initial HA content by HPLC and ELISA, respectively. The vaccine was administered to two groups of mice, one by microneedles and the other by intramuscular injection (IM). In vivo efficacies in the two groups were found to be similar, and cross-protection efficacy was also similar in both groups. HPLC exhibited good diagnostic performance with H3N2 microneedle vaccines and good agreement with ELISA. The H3N2 microneedle vaccines elicited a cross-protective immune response against the H3N2 antigenic variants. Here, we propose the use of HPLC for a more rapid approach in preparing H3N2 microneedle vaccines targeting H3N2 virus variants.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results